Literature DB >> 8483396

A multiattribute-utility-function approach to weighing the risks and benefits of pharmaceutical agents.

S Eriksen1, L R Keller.   

Abstract

Both the selection of doses of pharmaceutical agents and comparisons between pharmaceutical agents have long been based on the nonquantified concept of the risk-benefit ratio. Though useful, this concept implies a data comparison that is difficult to make: the toxicity versus the efficacy of a drug compound. This research demonstrates an approach for weighing risks and benefits by combining utility functions for human efficacy and toxicity with animal and laboratory toxicity information to develop an overall multiattribute utility function for an ophthalmic pharmaceutical agent, I-bunolol, intended for the treatment of glaucoma. With this multiattribute function and a small portion of the published data available for this drug, the expected utilities for six doses (including a control) could be compared and the value of this approach in drug-dosage selection demonstrated.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8483396     DOI: 10.1177/0272989X9301300205

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  6 in total

Review 1.  The use of clinical utility assessments in early clinical development.

Authors:  Anis A Khan; Itay Perlstein; Rajesh Krishna
Journal:  AAPS J       Date:  2009-01-16       Impact factor: 4.009

Review 2.  Integration of PKPD relationships into benefit-risk analysis.

Authors:  Francesco Bellanti; Rob C van Wijk; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2015-07-29       Impact factor: 4.335

3.  The use of multiattribute decision models in evaluating triptan treatment options in migraine.

Authors:  M D Ferrari; P J Goadsby; R B Lipton; D W Dodick; F M Cutrer; D McCrory; P Williams
Journal:  J Neurol       Date:  2005-03-11       Impact factor: 4.849

Review 4.  Prioritizing treatment attributes and their impact on selecting an oral triptan: results from the TRIPSTAR Project.

Authors:  David W Dodick; Richard B Lipton; Michel D Ferrari; Peter J Goadsby; Douglas McCrory; F Michael Cutrer; Paul Williams
Journal:  Curr Pain Headache Rep       Date:  2004-12

5.  A multi-attribute model of prostate cancer patient's preferences for health states.

Authors:  G B Chapman; A S Elstein; T M Kuzel; R B Nadler; R Sharifi; C L Bennett
Journal:  Qual Life Res       Date:  1999-05       Impact factor: 4.147

Review 6.  The application of adverse drug reaction data to drug choice decisions made by pharmacy and therapeutics committees. An Australian perspective.

Authors:  L M Weekes; R O Day
Journal:  Drug Saf       Date:  1998-03       Impact factor: 5.606

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.